Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy

Raúl de Los Ríos, Alejandro Bussalleu, Abdías Hurtado, José Valdivia, Jorge Huerta Mercado, Carlos Battilana, Marco Pala, José Luís Pinto, Alejandro Piscoya, Hugo Cedrón

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The prevalence of hepatitis C varies according to geographical areas and risk groups. Patients with terminal chronic renal failure (TCRF) under dialysis are an important risk group. In Peru, hepatitis C virus (HCV) infection rates in patients under hemo-dialysis reach 90%, and are associated with transfusions and time under dialysis as risk factors.Little is known about the prevalence of HCV in patients with TCRF receiving non dialysis therapy. The purpose of this study is to know the prevalence of HCV infection in these patients and to determine the risk factors. METHODOLOGY: Prospective study, anti-hepatitis C (anti HCV) antibodies were assessed in patients with TCRF in non-dialysis conservative therapy at the Department of Nephrology of the Arzobispo Loayza Hospital. RESULTS: Ninety nine (99) patients were studied, 54.1% male and 45.8% female, with an average age of 56.6 + 17.9 years, with an average time of CRF diagnosis of 9.28 + 14.35 months. The most frequent cause of CRF was the unknown cause, followed by diabetes. A rate of anti HCV of 1.01% (1/99) was found. CONCLUSION: A low prevalence of antiHCV was found in the population studied. It was similar to the rates found in populations without CTRF.

Translated title of the contributionPrevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy
Original languageSpanish
Pages (from-to)265-270
Number of pages6
JournalRevista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
Volume26
Issue number3
StatePublished - 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy'. Together they form a unique fingerprint.

Cite this